Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx

Ahmed I Ghanem,Marissa Gilbert,Chun‐Hui Lin,Christian E Keller,Glendon M Gardner,Ross Mayerhoff,Farzan Siddiqui
DOI: https://doi.org/10.1002/lary.31786
IF: 2.97
2024-09-27
The Laryngoscope
Abstract:Laryngeal CIS can be treated with a wide range of modalities including RT which has better recurrence‐free survival than non‐RT modalities. Nevertheless, this was not translated to better invasive laryngeal SCC progression or overall survival and was associated with lower rates of laryngeal preservation. As a first‐line treatment, non‐RT modalities were more commonly used in patients with higher comorbidities. With non‐inferior long‐term outcomes, RT can be reserved for a second‐line approach. Objective To compare survival endpoints in patients with laryngeal carcinoma in situ (L‐CIS) who received definitive radiotherapy (RT) versus other modalities as first‐line treatment and after disease recurrence. Methods This is a retrospective study of patients with L‐CIS treated between June 2001 and December 2021. Survival outcomes (recurrence‐free (RFS), invasion‐free (IFS), laryngectomy‐free (LFS), and overall survival (OS)) were compared between patients who had first‐line RT versus non‐RT modalities and for patients with recurrent disease who underwent second‐line RT. Results A total of 85 patients with L‐CIS were included (73 men [85.9%] and 12 [14.1%] women, median age of 65 [IQR: 55–74] years). Of these, 42 had first‐line RT (49.4%) and 43 (50.6%) had non‐RT treatment. After median follow‐up of 4.8 (IQR: 2.8–9) years, patients in the first‐line RT group had improved 2‐year (94.2% [95% confidence interval (CI): 86.7–100] versus 41.7% [CI: 29.3–59.5]) and 5‐year (90.6% [CI: 80.9–100] versus 27.5% [CI: 16.4–48.2]) RFS relative to non‐RT recipients (p
medicine, research & experimental,otorhinolaryngology
What problem does this paper attempt to address?